Epalinges, Switzerland
Hedera Dx, founded in 2021, is a Swiss-based startup in the Health Care industry, poised to revolutionize cancer diagnostics. With the slogan, "Modern cancer care to the next billion people," the company offers innovative NGS-based liquid biopsies. These non-invasive tests not only facilitate early diagnosis but also empower personalized treatment selection and ongoing disease monitoring.
Recently, Hedera Dx secured a significant funding boost with a €15.00M Series A investment on 27 May 2025. Esteemed venture capital firms such as Inventure, Tesi, Vsquared Ventures, Eyrir Venture Management, Helsana HealthInvest, and Top Harvest participated in this round, underscoring strong investor confidence.
The company's mission and innovative culture prioritize patient access to cutting-edge medical technology, positioning it for growth in a globally critical sector. Hedera Dx represents an attractive opportunity for investors seeking impactful ventures in the healthcare diagnostics landscape.
